Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection

摘要

Treatment of rheumatoid arthritis (RA) with biological agents in patients who have viral hepatitis is problematic and difficult. So far, little is known about the safety of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody, in RA patients with hepatitis B or C virus infection [1, 2]. Here, we report a patient with RA who was a hepatitis C virus (HCV) carrier, in whom there were no deleterious effects on liver function and viral load during treatment with TCZ.